Pseudohypericin

Pseudohypericin is a naphthodianthrone compound derived from Hypericum perforatum (St. John's Wort) that exhibits anti-inflammatory, mood-modulating, and stress-regulating properties. Its primary mechanisms involve inhibition of pro-inflammatory mediators, dopamine-β-hydroxylase enzyme activity, and antagonism of corticotropin-releasing factor 1 (CRF1) receptors.

Origin & History

Pseudohypericin is a black-red aromatic polycyclic dione naturally occurring in Hypericum perforatum (St. John's wort), concentrated in leaves, flowers, and reproductive parts, peaking during flowering. It is typically isolated via methanol or ethanol extraction followed by HPLC purification, yielding ≥98% pure powder (C₃₀H₁₆O₉, MW 520.5).

Historical & Cultural Context

As a component of Hypericum perforatum, pseudohypericin has been part of European folk medicine since ancient Greek and Roman times, referenced by Hippocrates and Pliny for wound healing and mood disorders. Western herbalism traditionally used St. John's wort teas and tinctures from the 17th-19th centuries for 'nervous disorders' and melancholy.

Health Benefits

• Anti-inflammatory activity: Inhibits LPS-induced PGE2/TNF-α at 0.03 µM in preclinical models (preliminary evidence)
• Potential mood support: Inhibits dopamine-β-hydroxylase (IC50=3 µg/mL), reducing norepinephrine synthesis (in-vitro evidence only)
• CRF1 receptor antagonism: May modulate stress response pathways (mechanism-based, no human trials)
• Antiviral properties: Shows activity against enveloped viruses including HIV in preclinical studies (not confirmed in human trials)
• PKC inhibition: IC50=15 µg/mL may contribute to antiretroviral activity (in-vitro data only)

How It Works

Pseudohypericin suppresses LPS-induced prostaglandin E2 (PGE2) and tumor necrosis factor-alpha (TNF-α) production at concentrations as low as 0.03 µM, indicating potent anti-inflammatory activity at the cyclooxygenase and cytokine signaling level. It inhibits dopamine-β-hydroxylase (DBH) with an IC50 of approximately 3 µg/mL, reducing the enzymatic conversion of dopamine to norepinephrine and thereby influencing catecholamine balance. Additionally, pseudohypericin acts as an antagonist at CRF1 receptors, potentially dampening hypothalamic-pituitary-adrenal (HPA) axis overactivation under stress conditions.

Scientific Research

No dedicated randomized controlled trials exist for isolated pseudohypericin. Pharmacokinetic data comes from small studies (n=12-18) using St. John's wort extracts, showing Cmax=10.2 ng/mL, t½=17.19 hr, with good tolerability. Despite promising preclinical antiviral/antiretroviral effects, these have not translated to human RCTs.

Clinical Summary

The majority of pseudohypericin research consists of in-vitro and preclinical (animal) studies, with very few isolated clinical trials examining this compound specifically rather than whole St. John's Wort extracts. Anti-inflammatory effects demonstrating PGE2 and TNF-α suppression have been quantified in cell-based LPS models at 0.03 µM, but these findings have not been validated in human randomized controlled trials. Dopamine-β-hydroxylase inhibition has been characterized in enzymatic assays with an IC50 of 3 µg/mL, though no human pharmacokinetic or dose-response data currently establish clinically relevant plasma concentrations. Overall, evidence remains preliminary and exploratory; conclusions about efficacy in humans cannot be drawn without dedicated clinical investigation.

Nutritional Profile

Pseudohypericin is not a nutrient or food but a naturally occurring naphthodianthrone compound (C30H16O9, MW ~520.44 g/mol) found primarily in Hypericum perforatum (St. John's Wort) and related Hypericum species. It is structurally related to hypericin, differing by one additional hydroxyl group. Key details: • Concentration in St. John's Wort aerial parts: approximately 0.03–0.3% dry weight, typically present at roughly 2–4× the concentration of hypericin in the plant material; standardized St. John's Wort extracts (e.g., 0.3% total hypericins) contain pseudohypericin as the major naphthodianthrone constituent. • Bioactive classification: Polycyclic quinone (naphthodianthrone); functions as a photosensitizing pigment with photoactivatable properties (absorption maxima ~548 nm and ~590 nm). • Bioavailability: Oral bioavailability is low and variable; pseudohypericin reaches peak plasma concentrations (Cmax ~2.7–15 ng/mL after ~300 mg standardized extract doses) within approximately 2–3 hours, with a shorter elimination half-life (~16–24 hours) compared to hypericin (~24–48 hours). It is highly protein-bound (>95%) in plasma. Photodegradation can reduce stability if not protected from light. • No macronutrient content (no protein, fat, carbohydrate, or fiber). • No vitamin or mineral content. • Solubility: Poorly water-soluble; moderately soluble in organic solvents (DMSO, methanol, ethanol). Formulation in lipid-based or micellar delivery systems may enhance absorption. • Co-occurring bioactives in source plant: Typically found alongside hypericin, hyperforin, flavonoids (quercetin, rutin, hyperoside), and phenolic acids, which may contribute to synergistic pharmacological effects.

Preparation & Dosage

No clinically studied dosages exist for isolated pseudohypericin. In St. John's wort extracts standardized to 0.3% hypericins (~0.2% pseudohypericin), typical doses are 300-900 mg/day divided, yielding plasma Cmax ~8-10 ng/mL. Research use concentrations: IC50=15 µg/mL for PKC inhibition, 3 µg/mL for dopamine-β-hydroxylase. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Hypericin, hyperforin, quercetin, chlorogenic acid, St. John's wort extract

Safety & Interactions

Pseudohypericin, as a constituent of St. John's Wort, shares the well-documented drug interaction profile of that plant, including potent induction of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein, which can significantly reduce plasma levels of medications such as cyclosporine, antiretrovirals, oral contraceptives, and warfarin. Photosensitivity reactions are a recognized concern with hypericin-class compounds, and individuals with fair skin should exercise caution with oral supplementation and sun exposure. Pseudohypericin is contraindicated during pregnancy and breastfeeding due to insufficient safety data and theoretical risks related to catecholamine modulation and HPA axis interference. Concurrent use with serotonergic antidepressants, MAO inhibitors, or triptans carries a theoretical risk of serotonin syndrome and should be avoided without medical supervision.